The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A first-in-human first-in-class (FIC) trial of the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with advanced solid tumours.
 
Sarah E. R. Halford
No Relationships to Disclose
 
Paul Jones
No Relationships to Disclose
 
Steve Wedge
Stock and Other Ownership Interests - AstraZeneca
Consulting or Advisory Role - Astex Pharmaceuticals
Research Funding - Astex Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Cancer Research Technology
 
Sandra Hirschberg
Stock and Other Ownership Interests - GlaxoSmithKline
 
Sidath Katugampola
No Relationships to Disclose
 
Gareth Veal
Consulting or Advisory Role - Novartis (Inst); Sanofi (Inst)
 
Geoffrey Payne
No Relationships to Disclose
 
Chris Bacon
No Relationships to Disclose
 
Sarah Potter
No Relationships to Disclose
 
Melanie Griffin
Patents, Royalties, Other Intellectual Property - Astex Pharmaceuticals; AstraZeneca; Pfizer
 
Maxime Chenard-Poirier
No Relationships to Disclose
 
George Petrides
Travel, Accommodations, Expenses - GE Healthcare
 
Graham Holder
Consulting or Advisory Role - International Society of the Arts, Mathematics, and Architecture; Roche; SERVIER
 
Hector C Keun
No Relationships to Disclose
 
Udai Banerji
Employment - Institute of Cancer Research
Consulting or Advisory Role - Astex Pharmaceuticals; Novartis
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Onyx (Inst)
 
Elizabeth R. Plummer
Honoraria - Bristol-Myers Squibb; Roche/Genentech
Consulting or Advisory Role - Astex Pharmaceuticals; AstraZeneca; Bayer; Clovis Oncology; Karus Therapeutics; Mission Therapeutics; MSD Oncology; Novartis; Pierre Fabre; Roche/Genentech; Vertex
Speakers' Bureau - Novartis
Research Funding - AstraZeneca/MedImmune (Inst); Clovis Oncology (Inst); Eisai (Inst); Etherapeutics (Inst); Ipsen (Inst); vertex (Inst)
Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst)
Travel, Accommodations, Expenses - MSD Oncology